Meropenem Sandoz (Meropenem Trihydrate)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins (PBPs). This blocks the cross‑linking of peptidoglycan strands, weakening the cell wall and causing osmotic lysis. Its high affinity for multiple PBPs provides activity against a wide range of resistant bacteria.

The dosage of Meropenem Sandoz is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Dosing regimens are individualized and should follow the prescriber’s instructions.

Safety data for meropenem in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case and discuss potential risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Meropenem shares the carbapenem class’s broad‑spectrum activity but offers a slightly lower risk of neurotoxicity compared with imipenem and a more favorable dosing schedule than ertapenem for certain infections. Choice of carbapenem depends on local resistance patterns, infection site, and patient-specific factors.

Meropenem Sandoz should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze the solution, and avoid shaking the vial to maintain stability. If the product reaches room temperature, it should be used promptly.

Meropenem Sandoz is supplied as an intravenous solution and is administered by slow infusion into a vein, typically over 15‑30 minutes. The infusion rate and duration are set by the healthcare professional based on the prescribed dose and patient tolerance.

The most serious adverse events include anaphylactic reactions, seizures (especially in patients with renal impairment or high doses), and Clostridioides difficile‑associated colitis. Prompt recognition and discontinuation of the drug are essential if any of these events occur.

Patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation should avoid the drug. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those taking medications that lower the seizure threshold.